EMA Accepts Marketing Application for Cevira

Cevira is a photodynamic drug-device combination product, a targeted therapy that uses a photosensitizing agent, hexylaminolevulinate, activated by light to treat diseased tissue. The treatment is designed to be non-invasive, preserving healthy cervical tissue, a significant advantage over surgical options like LEEP or conization which can be associated with bleeding, infection, and risks to future pregnancies. The international, multicenter Phase III clinical trial for Cevira demonstrated statistically significant efficacy. The response rate in the treatment group was 89.4% higher than in the placebo group (41.1% vs. 21.7%). Additionally, Cevira showed a 103.9% greater clearance rate of high-risk HPV16 and/or HPV18 compared to the placebo. The worldwide rights for the development and commercialization of Cevira were licensed by its developer, Photocure, to Asieris Pharmaceuticals in 2019. This agreement has a potential value of up to $250 million for Photocure, which includes a $5 million signing fee, up to $36 million for clinical and regulatory milestones in the US and EU, and tiered royalties ranging from 10% to 20%. Upon potential approval in Europe and the U.S., Photocure is entitled to a $36 million milestone payment. Asieris has been actively preparing for commercialization, including establishing a dedicated Women's Health Business Unit to manage the launch and distribution of Cevira. The standard review process for a Marketing Authorization Application by the European Medicines Agency takes approximately 210 days, not including potential "clock stops" for the company to provide additional information. For a product of major public health interest, an accelerated assessment of 150 days can be requested. While other topical, non-surgical treatments for high-grade cervical lesions, such as imiquimod and 5-fluorouracil, are being researched, none are as advanced in the clinical trial process as Cevira, positioning it as a potential first-in-class, non-surgical option. Another non-invasive technology, non-invasive physical plasma, is also in earlier, phase IIb trials. The prevalence of high-grade squamous intraepithelial lesions (HSIL) in Europe varies, with one study in France showing an overall prevalence of 0.4% in the screened population. The prevalence was notably higher in younger women, reaching 0.81% in the 25-29 age group.